Research and Development for Genome Reference Representations (GRR) (U01 Clinical Trial Not Allowed)

The summary for the Research and Development for Genome Reference Representations (GRR) (U01 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Research and Development for Genome Reference Representations (GRR) (U01 Clinical Trial Not Allowed): The National Human Genome Research Institute (NHGRI) seeks to support research and development for a next-generation genome reference representation. This pangenome resource will be able to capture all human genome variation and support scalable analysis in a software framework that will set a robust foundation for open science. Projects will develop improved representations for computing on the information contained within the increasing numbers of diverse genome assemblies that will make up the human reference sequence going forwards. While the high-level concept of the pangenome as a graph is well-established, further research and development is needed to refine and implement a practical representation and implementation to enable active use of population-scale variation. Software is needed that can demonstrate efficiency, scalability, computational speed, ease of use, and the ability to foster adoption of the reference and analysis tool development for a wide range of purposes. The FOA will fund multiple projects that will together help set benchmarks and standards in this domain. A primary requirement is to adhere to a high level of open science including open-source tools, standards, specifications, and robust software engineering to enable this core resource to be widely integrated in the larger community and support outside contributions. Robust design is also expected to provide a foundation for independent efforts that may have enhanced privacy and security requirements.

Federal Grant Title:	Research and Development for Genome Reference Representations (GRR) (U01 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HG-19-003
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.172
CFDA Descriptions:	Information not provided
Current Application Deadline:	April 2nd, 2019
Original Application Deadline:	April 2nd, 2019
Posted Date:	January 30th, 2019
Creation Date:	January 30th, 2019
Archive Date:	May 8th, 2019
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	January 30th, 2019

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-19-003.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Addressing Health Inequities in Clinical Diagnostics (R41/R42 Clinical Trials Not Allowed); • Addressing Health Inequities in Clinical Diagnostics (R43/R44 Clinical Trials Not Allowed); • NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed); • Solutions to Enable Regional Genomic Medicine eConsult Services (R41/R42 Clinical Trial Op...; • Research on the Impact of and Methods for Implementing Regional Genomic Medicine eConsult ...; • Near-Term Technology Development for Genome Sequencing - SBIR (R43/R44); • Near-Term Technology Development for Genome Sequencing - STTR (R41/R42); • Revolutionary Genome Sequencing Technologies - The $1000 Genome - SBIR (R43/R44)
More Grants from the National Institutes of Health: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...